Combination therapy shows potent tumor growth inhibition in preclinical studies
Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC ...
Nov 13, 2011
0
0